Dabomb Protein Biotech (ROCO:6578) Payments of Debt: NT$-308.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6578 Dabomb Protein Biotech Corp ROCO:6578
58 GF Score
Price NT$18.25
GF Value NT$16.58
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Dabomb Protein Biotech Payments of Debt?

Dabomb Protein Biotech ROCO:6578 +9.94% 58 Payments of Debt is NT$-308.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6578 with a GF Score™ of 58/100 and a GF Value™ of NT$16.58 (Fairly Valued). The stock has 1 warning sign investors should review.

Dabomb Protein Biotech's Payments of Debt for the three months ended in Mar. 2026 was NT$-35.7 Mil.

Dabomb Protein Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-308.0 Mil.

Dabomb Protein Biotech Payments of Debt Related Terms

Dabomb Protein Biotech Payments of Debt Historical Data

* Premium members only.

The historical data trend for Dabomb Protein Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dabomb Protein Biotech Payments of Debt Chart

Dabomb Protein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -270.54 -178.69 -526.74 -342.37 -319.08

Dabomb Protein Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.84 -59.75 -83.85 -128.64 -35.74
ROCO:6578
58GF Score
Dabomb Protein Biotech Corp ROCO:6578
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dabomb Protein Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-308.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of NT$-308.0 Mil mean?
Dabomb Protein Biotech (ROCO:6578) has a Payments of Debt of NT$-308.0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Payments of Debt too high?
Dabomb Protein Biotech's current Payments of Debt is NT$-308.0 Mil. Overall, Dabomb Protein Biotech has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Payments of Debt compare to KHC and GIS?
Dabomb Protein Biotech's Payments of Debt of NT$-308.0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Consumer Packaged Goods company?
A good Payments of Debt depends on the Consumer Packaged Goods industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Dabomb Protein Biotech and its competitors. Dabomb Protein Biotech's current Payments of Debt is NT$-308.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$16.58, compared to a current price of NT$18.25 — trading 10.1% above its estimated fair value. The current Payments of Debt is NT$-308.0 Mil. Dabomb Protein Biotech's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Payments of Debt is NT$-308.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?

Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued. The current stock price of NT$18.25 is trading 10.1% above its estimated GF Value™ of NT$16.58. GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.

Key valuation signals for ROCO:6578:

  • Payments of Debt: NT$-308.0 Mil
  • GF Value™: NT$16.58 vs. price of NT$18.25 (10.1% above fair value)
  • GF Score™: 58/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dabomb Protein Biotech Business Description

Address No. 52, Industrial 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
58GF Score

Get the complete analysis for ROCO:6578

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.25
Price
NT$16.58
GF Value